2021
DOI: 10.1128/aac.01383-20
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse–Berenice-78 Trypanosoma cruzi Strain Model

Abstract: Chronic Chagas disease might have an impact on benznidazole pharmacokinetics with potential alterations in the therapeutic dosing regimen. The study aims to investigate the influence of chronic T. cruzi infection on the pharmacokinetics and biodistribution of benznidazole in mice. Healthy (n = 40) and chronically T. cruzi (Berenice-78 strain) infected (n = 40) Swiss female 10-month old mice received a single oral dose of 100 mg/kg benznidazole. Serial blood, heart, colon and brain samples were collected up to … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
4
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 41 publications
0
4
0
Order By: Relevance
“…The disease is characterized by an acute and a chronic phase, and approximately 30 to 40% of chronically infected individuals develop overt clinical forms, such as cardiac and digestive ones 2 . There are two drugs available to treat the disease, nifurtimox and benznidazole (BZD); the last is the drug of choice in Brazil 3 .…”
Section: Introductionmentioning
confidence: 99%
“…The disease is characterized by an acute and a chronic phase, and approximately 30 to 40% of chronically infected individuals develop overt clinical forms, such as cardiac and digestive ones 2 . There are two drugs available to treat the disease, nifurtimox and benznidazole (BZD); the last is the drug of choice in Brazil 3 .…”
Section: Introductionmentioning
confidence: 99%
“…The understanding of the pathogenesis of Chagas disease and of the roles played by animal models towards the T. cruzi infections translated into the disease clinical manifestations is essential to accomplish the drug treatment objectives [58,59,60]. In this regard, the rodent (Mus musculus) model highly susceptible to the T. cruzi infections are mostly used to monitor the drug killing of the trypanosomes and assessments of a satisfactory treatment of the disease [62,63]. The rabbit (Chordata, Lagomorpha) and the dog (Carnivora, Cannis Lupus familiaris) are relatively resistant to an early infection, but they die of chronic chagas heart disease usually over one year after the acquisition of the T. cruzi infection [63][64][65].…”
Section: Introductionmentioning
confidence: 99%
“…The administration of the nitro heterocyclic may induce severe hypersensitive reactions, dermatitis, polyneuritis, joint and muscle pain, neutropenia, bone marrow depression, paresthesia, and convulsion. The drug toxicity precludes the completion of the full treatment, and the proportion of failure is high [60][61][62][63][64]. In addition, the nitro heterocyclics are considered unsatisfactory because the long-lasting treatment (60 to 90 days) do not clear the parasite from the host´s body [62][63][64][65][66][67][68][69].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation